Irish journal of medical science · 2025
Impact of royal jelly consumption on oxidative stress, anti-oxidant markers and physical activities of patients with multiple sclerosis: a randomized double-blind placebo-controlled study.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eslamifar Zahra, Manucheri Farzaneh, Ghanbari Saeed, Zandi Mohammadreza, Sabbagh Susan
Аннотация
BACKGROUND: The study investigates the effects of royal jelly (RJ) on patients with relapsing-remitting multiple sclerosis (RRMS), focusing on its potential to reduce oxidative stress, improve antioxidant levels, and enhance quality of life.
METHODS: A total of 61 RRMS patients were randomly assigned to either a RJ group or a placebo group, receiving a daily dose of 500 mg for 45 days. Key outcomes measured included expanded disability status scale (EDSS) scores, levels of malondialdehyde (MDA), and activities of antioxidants such as catalase (CAT) and superoxide dismutase (SOD), along with assessments of fatigue and quality of life.
RESULTS: Results indicated that the RJ group experienced a significant reduction in EDSS scores (P < 0.001) and MDA levels (P < 0.0001). The activity of SOD and CAT after consumption of RJ had increased significantly (P < 0.0001, P < 0.001), respectively. Additionally, improvements were noted in some parameters of fatigue and quality of life measures.
CONCLUSION: The findings suggest that RJ may help decrease oxidative stress and improve motor function and anti-oxidant capacity in MS patients, potentially slowing disease progression.
TRIAL REGISTRATION: This study was registered on the Iranian Registry of Clinical Trials (Registration No. IRCT20220116053732N1) on 2022.05.08.
METHODS: A total of 61 RRMS patients were randomly assigned to either a RJ group or a placebo group, receiving a daily dose of 500 mg for 45 days. Key outcomes measured included expanded disability status scale (EDSS) scores, levels of malondialdehyde (MDA), and activities of antioxidants such as catalase (CAT) and superoxide dismutase (SOD), along with assessments of fatigue and quality of life.
RESULTS: Results indicated that the RJ group experienced a significant reduction in EDSS scores (P < 0.001) and MDA levels (P < 0.0001). The activity of SOD and CAT after consumption of RJ had increased significantly (P < 0.0001, P < 0.001), respectively. Additionally, improvements were noted in some parameters of fatigue and quality of life measures.
CONCLUSION: The findings suggest that RJ may help decrease oxidative stress and improve motor function and anti-oxidant capacity in MS patients, potentially slowing disease progression.
TRIAL REGISTRATION: This study was registered on the Iranian Registry of Clinical Trials (Registration No. IRCT20220116053732N1) on 2022.05.08.